Contract Manufacturing In India

10,575 views
10,282 views

Published on

Published in: Business
1 Comment
2 Likes
Statistics
Notes
No Downloads
Views
Total views
10,575
On SlideShare
0
From Embeds
0
Number of Embeds
17
Actions
Shares
0
Downloads
376
Comments
1
Likes
2
Embeds 0
No embeds

No notes for slide

Contract Manufacturing In India

  1. 1. Kaushik Sampathkumar Project Manager, Business Development Inogent Laboratories (GVK BIO company) India
  2. 2. <ul><li>Market Overview </li></ul><ul><ul><li>Reality check </li></ul></ul><ul><ul><ul><li>Generic surge </li></ul></ul></ul><ul><ul><ul><li>Laws of diminishing returns </li></ul></ul></ul><ul><ul><ul><li>Innovators losing ground </li></ul></ul></ul><ul><ul><ul><li>Pipeline choke </li></ul></ul></ul><ul><ul><ul><li>Global R&D spend </li></ul></ul></ul><ul><ul><ul><li>Indian CMO growth </li></ul></ul></ul><ul><li>Indian Players – Aligning for Growth </li></ul><ul><ul><li>Strengths </li></ul></ul><ul><ul><ul><li>Cost of operations, API expertise, Regulatory & FDA understanding, Infrastructure & Market economics </li></ul></ul></ul><ul><ul><li>Weakness </li></ul></ul><ul><ul><ul><li>Quality practices & compliance, Logistics </li></ul></ul></ul><ul><ul><li>Opportunities </li></ul></ul><ul><ul><ul><li>TRIPS agreement, Early mover advantage, Government subsidy (Pharma SEZ), Domestic market </li></ul></ul></ul><ul><ul><li>Threat </li></ul></ul><ul><ul><ul><li>China </li></ul></ul></ul>
  3. 3. <ul><li>Market Overview </li></ul><ul><ul><li>Reality check </li></ul></ul><ul><ul><ul><li>Generic surge </li></ul></ul></ul><ul><ul><ul><li>Laws of diminishing returns </li></ul></ul></ul><ul><ul><ul><li>Innovators losing ground </li></ul></ul></ul><ul><ul><ul><li>Pipeline choke </li></ul></ul></ul><ul><ul><ul><li>Global R&D spend </li></ul></ul></ul><ul><ul><ul><li>Indian CMO growth </li></ul></ul></ul><ul><li>Indian Players – Aligning for Growth </li></ul><ul><ul><li>Strengths </li></ul></ul><ul><ul><ul><li>Cost of operations, API expertise, Regulatory & FDA understanding, Infrastructure & Market economics </li></ul></ul></ul><ul><ul><li>Weakness </li></ul></ul><ul><ul><ul><li>Quality practices & compliance, Logistics </li></ul></ul></ul><ul><ul><li>Opportunities </li></ul></ul><ul><ul><ul><li>Early mover advantage, Government subsidy (Pharma SEZ), Domestic market </li></ul></ul></ul><ul><ul><li>Threat </li></ul></ul><ul><ul><ul><li>China </li></ul></ul></ul>
  4. 4. <ul><li>Next year, 2011, will be the toughest for the top 50 pharma companies who have $31b coming off patent </li></ul><ul><li>Generics erosion is highest in the US, average erosion is 95% observed in the 3 rd quarter following first entry </li></ul><ul><li>Competition and cost cutting are driving down margins in the industry leading to consolidation </li></ul>Sales exposed to generic erosion for the top 50 pharma companies through 2014 Source: Datamonitor, PharmaVitae Explorer, November 2009
  5. 5. <ul><li>The R&D spend increases by 100% while the approvals tumble down by 80% </li></ul>
  6. 6. Source: Datamonitor. Pharmaceutical Company Outlook to 2014. Dec 2009. The 2002-08 CAGR was 10.5%...highlighting the challenges pharma is facing today…… Prescription sales growth rate is stalled at about 1.2% - largely due to the much discussed ‘patent cliff’
  7. 8. Patent cliff is nearly 6x that in 2002-2008 Pfizer’s Lipitor comes off patent in 2011 and had $12.4b in 2008 sales Core sales also highly impacted by indirect generic competition Source: Datamonitor. Pharmaceutical Company Outlook to 2014. Dec 2009.
  8. 10. CAGR : 11.0% Revenue : $54.7 bn Revenue : $80.6 bn Source: Frost & Sullivan
  9. 11. Revenue : $5.31 bn Revenue : $2.31 bn Source: Frost & Sullivan
  10. 12. <ul><li>Market Overview </li></ul><ul><ul><li>Reality check </li></ul></ul><ul><ul><ul><li>Generic surge </li></ul></ul></ul><ul><ul><ul><li>Laws of diminishing returns </li></ul></ul></ul><ul><ul><ul><li>Innovators losing ground </li></ul></ul></ul><ul><ul><ul><li>Pipeline choke </li></ul></ul></ul><ul><ul><ul><li>Global R&D spend </li></ul></ul></ul><ul><ul><ul><li>Indian CMO growth </li></ul></ul></ul><ul><li>Indian Players – Aligning for Growth </li></ul><ul><ul><li>Strengths </li></ul></ul><ul><ul><ul><li>Cost of operations, API expertise, Regulatory & FDA understanding, Infrastructure & Market economics </li></ul></ul></ul><ul><ul><li>Weakness </li></ul></ul><ul><ul><ul><li>Quality practices & compliance, Logistics </li></ul></ul></ul><ul><ul><li>Opportunities </li></ul></ul><ul><ul><ul><li>TRIPS agreement, Early mover advantage, Government subsidy (Pharma SEZ), Domestic market </li></ul></ul></ul><ul><ul><li>Threat </li></ul></ul><ul><ul><ul><li>China </li></ul></ul></ul>
  11. 13. <ul><li>API costs account for around 30 per cent of the total cost of a generic drug . This does not impact patented products as much as cost competitive generic medications. The price of a generic formulation is highly dependent upon the cost of APIs and companies attempt to determine firms, which can provide APIs with stable costs. This has resulted in a growing demand for contract manufacturers who produce pre-determined products at prices fixed in advance. The contract manufacturing market comprises of bulk drugs as well as formulations. However, the bulk drug contract manufacturing contributes to 77 per cent of the total contract manufacturing market . India has emerged as one of the prime destinations for contract manufacturing due to its low cost and high efficient manufacturing processes. Many international companies have invested in contract manufacturing assets in India. India has a cost advantage unrivalled by many countries, while offering state-of-the-art manufacturing facilities . Considering the advantages offered by India, innovator companies are opting India for contract manufacturing. This is further strengthened by the fact that many innovator companies have in recent years focused on cost cutting and thereby have closed down or sold their manufacturing units. In recent years contract manufacturing has emerged as a major revenue source for Indian companies. Contract manufacturing is a growing industry in the country. As more and more innovator companies are reducing manufacturing spend, there would definite increase in the companies that offer contract manufacturing services. </li></ul><ul><li>The US Senate has approved the Healthcare Bill, which entails expanding the insurance coverage to citizens either employed with smaller companies or unemployed. It is estimated that around 3.2cr US citizens would now receive additional healthcare access. This development augurs well for Indian CMO industry </li></ul>
  12. 14. <ul><li>Adding capacities and capabilities </li></ul><ul><li>Partnerships </li></ul><ul><ul><li>Ranbaxy – Eli Lilly, Lupin –Cynamid, Cadila –Byk Gulden, Aurobindo – Pfizer, Dr. Reddy’s – GSK Plc, Strides Arcolabs – Pfizer, Claris Lifescience – Pfizer </li></ul></ul><ul><li>M&As </li></ul><ul><ul><li>Dr Reddy's Laboratories (DRL) acquired betapharm from Germany for €480 million </li></ul></ul><ul><ul><li>Sun Pharma acquired US-based Able Laboratories and the manufacturing facilities of ICN in Eastern E </li></ul></ul><ul><ul><li>Shasun acquired Rhodia’s contract manufacturing operations </li></ul></ul><ul><ul><li>Detailed list </li></ul></ul>
  13. 15. <ul><li>Cost advantage </li></ul><ul><ul><li>Capital efficiency: Indian companies are able to reduce the upfront capital cost of setting up a project by 25-50 percent due to access to locally fabricated equipment and high quality local technology/engineering skills. This benefit can be passed on to customers. </li></ul></ul><ul><ul><li>Labor cost in India is typically in the range of 10-15 percent of similar costs in the US. </li></ul></ul><ul><li>Resource </li></ul><ul><ul><li>India has the world's second biggest pool of English speakers and a strong system of higher education </li></ul></ul><ul><ul><li>115,000 scientists with Masters degrees and 12,000 with PhDs every year </li></ul></ul><ul><li>API process development expertise </li></ul><ul><li>Regulatory & FDA </li></ul><ul><ul><li>Indian players jumped from around 14 per cent in 2000 to 46 per cent in 2008 (January-June) </li></ul></ul><ul><ul><li>India has recorded 1,671 DMF filings, China shows a tally of 520, the second largest number of DMF filings after India. Even in 2008 (January-June), India's DMF filings were around 3.5 times that of China - l8l and 51, respectively </li></ul></ul><ul><li>Market Economics </li></ul><ul><ul><li>The industry received investments worth Rs 21.4 bn in the form of FDI between April 2007 and April 2009. Out of 36 countries that contributed to FDI in India, 5 countries, led by Mauritius (56.4%), Singapore (11.2%), USA (5.8%), UAE (4.7%) and Canada (4.0%), accounted for over 82% of FDI in drugs and pharmaceuticals1. </li></ul></ul><ul><ul><li>According to the Ministry of Commerce and Industry, domestic investment in the industry is estimated at Rs 31.34 bn. </li></ul></ul>
  14. 16. <ul><li>Quality practices & compliance </li></ul><ul><ul><li>Recently major bulk drug companies of India have come under FDA scanner </li></ul></ul><ul><ul><li>September 08 - Ranbaxy's PAONTA SAHIB & MANESAR mfg unit were under the FDA scan & 30 drugs banned in US . </li></ul></ul><ul><ul><li>October 08 - Sun Pharma's Carcao mfg. unit ( Detroit ) - was the victim of FDA rage .  </li></ul></ul><ul><ul><li>April 09 - Cipla has been questioned for deviation from US FDA mfg. process .   </li></ul></ul><ul><li>Logistics </li></ul><ul><ul><li>The market size of Indian pharmaceutical logistics was $ 199.5 million in 2006 and the industry has been growing at an average annual growth rate of four percent since 2002 </li></ul></ul><ul><ul><li>Logistics and distribution has been Outsourcing companies’ most perceived risk area </li></ul></ul><ul><ul><li>Latent information asymmetry; loss of logistics innovative capacity; hidden costs; dependence on the third party logistics (3PL) providers; loss of control over the 3PL providers; </li></ul></ul>
  15. 17. <ul><li>Early Mover Advantage </li></ul><ul><li>Estimated USD 103 bn worth of global generic drugs are at the risk of losing their patents by 2012. </li></ul><ul><li>India is significantly ahead in chemistry services such as analogue preparation, analytical chemistry and structural drug design, which will provide the country with ample avenues in the field of contract manufacturing approved facilities and 200 cGMP manufacturing facilities </li></ul><ul><li>TRIPS agreement </li></ul><ul><li>The introduction of the new patent regime in India from January 2005 has boosted the confidence of multinational companies looking to outsource the manufacturing of branded drugs with the protection of intellectual property rights (IPRs). </li></ul><ul><li>Amendment to Schedule Y to allow parallel phase clinical trails </li></ul><ul><li>Government Subsidy </li></ul><ul><li>15 per cent capital subsidy for manufacturing facility investment and equipment projects. </li></ul><ul><li>SEZ – Pharmaceutical exclusive setups : Vizag and Himachal Pradesh </li></ul><ul><li>Domestic Market </li></ul><ul><li>The growing domestic market with TRIPS agreement in place presents opportunity for direct investments of Pharma MNCs in India </li></ul>
  16. 18. <ul><li>China and India together account for 7% of world pharmaceutical industry in value terms with revenues of US$28 billion. </li></ul><ul><li>FDI in pharmaceutical sector in China is more than 20 times than in Indian sector </li></ul><ul><li>18 of world top 20 companies have setup their manufacturing and R&D facilities in China </li></ul><ul><ul><li>GSK, Novo Nordisk, Boheringer Mannheim, Merck, Aventis all have their largest R&D </li></ul></ul><ul><li>China competing as bulk drug-sourcing base for MNC’s and global generic majors, by developing patent non-infringing processes for drugs on which the patent is set to expire </li></ul>
  17. 19. <ul><li>India has strong chemistry and regulatory skills, which have helped it emerge as a top </li></ul><ul><li>destination for Research and Development. India’s cost of manufacturing , highest number of US FDA approved plants outside the USA have been and continues to be advantageous . </li></ul><ul><li>Pfizer AstraZeneca, Merck, GSK, Solvay, Eli Lilly and others are very much part of India outsourcing story. MNCs are likely to scale up operations gradually as they get more experienced with Indian partners. </li></ul><ul><li>Over the years, Chinese companies have been aggressive in filing DMFs. Chinese </li></ul><ul><li>companies have filed over 60 DMFs in 2005 as compared to 40 in 2004. Over the next 2-3 years, </li></ul><ul><li>Chinese companies are likely to move up the value chain by venturing into high-end </li></ul><ul><li>intermediates and formulations </li></ul><ul><li>India is likely to account for 3-4 percent of the global contract outsourcing industry. From the </li></ul><ul><li>above estimates, it is evident that the Indian CRAMS story has just scaled the ‘tip of the iceberg’ and ‘sky is the limit’ for the companies that have ventured into this space . </li></ul>Source: Frost & Sullivan

×